Last reviewed · How we verify
NCT07335406: Hp-SHAREReg
Registry for the Management of Helicobacter Pylori Infection in Shandong Province
trial testing Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstance, not involve any intervention procedure. in HELICOBACTER PYLORI INFECTIONS in 10,000 participants. Currently enrolling.
1 November 2035
Quick facts
| Lead sponsor | Yueyue Li |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 February 2026 |
| Primary completion | 1 November 2035 |
| Estimated completion | 30 November 2035 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstance, not involve any intervention procedure.
Conditions studied
- HELICOBACTER PYLORI INFECTIONS — all drugs for HELICOBACTER PYLORI INFECTIONS →
Sponsor
Yueyue Li — full company profile →
Who can join
Adults 18 to 80, any sex, with HELICOBACTER PYLORI INFECTIONS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Helicobacter pylori infection is a common global gastrointestinal infectious disease, affecting approximately 43.1% of the world's population. Eradicating H. pylori is crucial for reducing the risk of developing conditions such as gastritis, peptic ulcer disease, and gastric cancer. Currently, 14-day high-dose dual therapy containing amoxicillin and bismuth-containing quadruple therapy are the guideline-recommended first-line treatment regimens for H. pylori eradication. Treatment options for H. pylori vary considerably, with differing efficacy outcomes largely attributable to increasing bacterial antibiotic resistance. Furthermore, multiple factors influence the efficacy of H. pylori eradication, including smoking, body surface area, CYP2C19 gene polymorphisms, patient compliance, and regional variations. Therefore, to systematically evaluate the efficacy and safety of different treatment regimens alongside the cost-effectiveness of various therapeutic strategies, and to conduct ongoing critical analysis of clinical practice, this study proposes a long-term investigation of real-world clinical practice through a non-interventional cohort study registry. This will assess the effectiveness, safety, and temporal trends of different H. pylori infection treatment regimens, providing real-time evidence to support clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07335406
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HELICOBACTER PYLORI INFECTIONS
Currently open trials in the same condition.
- NCT07293910 — Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Py · Phase 2 · recruiting
- NCT07346521 — Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa Durin · recruiting
- NCT07246681 — Lignin in Treatment of Helicobacter Pylori Infection · Phase 3 · active not recruiting
- NCT07179159 — Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication · NA · recruiting
- NCT07306988 — Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. · Phase 4 · recruiting
Other Yueyue Li trials
Trials by the same sponsor.
- NCT07352098 — 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori · NA · not yet recruiting
- NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
- NCT07333001 — Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helic · completed
- NCT07167511 — Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07335406 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yueyue Li
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07335406.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing